{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:37Z","timestamp":1766023117262,"version":"3.48.0"},"reference-count":30,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/vfdm5811","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:08:31Z","timestamp":1719533311000},"page":"2946-2956","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors for the outcome and prognosis of multiple myeloma patients with pathological fractures undergoing percutaneous vertebroplasty"],"prefix":"10.62347","volume":"14","author":[{"given":"Haining","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","article-title":"What is multiple myeloma","volume":"327","author":"Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S and Grant SJ. What is multiple myeloma. JAMA 2022; 327: 497.","journal-title":"JAMA"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S and Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021; 397: 2361-2371.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, Thomas CC, Islami F, Weir HK, Lewis DR, Sherman RL, Wu M, Benard VB, Richardson LC, Jemal A, Cronin K and Kohler BA. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2020; 126; 2225-2249.","DOI":"10.1002\/cncr.32802"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA and Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-1128.","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG and Delimpasi S. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020; 396: 1563-1573.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41587-023-01962-x","article-title":"FDA approves first-in-class bispecific for multiple myeloma","volume":"41","author":"Biotechnology","year":"2023","unstructured":"Biotechnology JN. FDA approves first-in-class bispecific for multiple myeloma. Nat Biotechnol 2023; 41: 1180.","journal-title":"Nat Biotechnol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41467-019-09555-6","article-title":"Multiple myeloma immunoglobulin lambda translocations portend poor prognosis","volume":"10","author":"Barwick","year":"2019","unstructured":"Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM and Boise LH. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nat Commun 2019; 10: 1911.","journal-title":"Nat Commun"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Osterhoff G, Kreinest M, Kuhnt T, Pohlenz C, Müller-Broich J, Röllig C, Teipel R, Scheyerer MJ, Schnake KJ, Spiegl UJA and Disch AC; Spine Section of the German Society for Orthopaedics and Trauma (DGOU). Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma: multidisciplinary recommendations. Global Spine J 2023; 13: 85S-93S.","DOI":"10.1177\/21925682221143732"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Burks JD, Elarjani T, Jamshidi AM, Govindarajan V and Levi AD. Vertebral multiple myeloma with pathological fracture: the most common etiology for emergency spine surgery in patients with no cancer diagnosis on admission. Neurosurg Focus 2021; 50: E2.","DOI":"10.3171\/2021.2.FOCUS201038"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.4081\/hr.2021.9037","article-title":"Low diagnostic accuracy and inter-observer agreement on CT and MRI in diagnosis of spinal fractures in multiple myeloma","volume":"13","author":"Dalen","year":"2021","unstructured":"Dalen V, Vegsgaard Olsen AS, Jerome CP, Geitung JT and Dahm AEA. Low diagnostic accuracy and inter-observer agreement on CT and MRI in diagnosis of spinal fractures in multiple myeloma. Hematol Rep 2021; 13: 9037.","journal-title":"Hematol Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.4103\/jfmpc.jfmpc_343_20","article-title":"An atypical presentation of multiple myeloma in a young patient with pathological fracture","volume":"9","author":"Kumar","year":"2020","unstructured":"Kumar B, Yadav P, Nadeem M and Garg MK. An atypical presentation of multiple myeloma in a young patient with pathological fracture. J Family Med Prim Care 2020; 9: 3154-3156.","journal-title":"J Family Med Prim Care"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hon.3102","article-title":"The role of vertebral augmentation procedures in the management of vertebral compression fractures secondary to multiple myeloma","volume":"41","author":"Eseonu","year":"2023","unstructured":"Eseonu KC, Panchmatia JR, Streetly MJ, Grauer JN and Fakouri B. The role of vertebral augmentation procedures in the management of vertebral compression fractures secondary to multiple myeloma. Hematol Oncol 2023; 41: 323-334.","journal-title":"Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV and Moreau P. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863-2869.","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","unstructured":"Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, Roberts S, Ingleson E, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Pratt G, Owen RG, Drayson MT, Brown SR and Jenner MW. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma. J Clin Oncol 2023; 41: 3945-3955.","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A and Sonneveld P; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375: 754-766.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jama.2022.7489","article-title":"Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment","volume":"328","author":"He","year":"2020","unstructured":"He S, Renne A, Argandykov D, Convissar D and Lee J. Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment. JAMA 2020; 328: 208-209.","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.3390\/cancers15143601","article-title":"Intramedullary nailing with and without the use of bone cement for impending and pathologic fractures of the humerus in multiple myeloma and metastatic disease","volume":"15","author":"Kobryn","year":"2023","unstructured":"Kobryn A, Nian P, Baidya J, Li TL and Maheshwari AV. Intramedullary nailing with and without the use of bone cement for impending and pathologic fractures of the humerus in multiple myeloma and metastatic disease. Cancers (Basel) 2023; 15: 3601.","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13018-019-1078-0","article-title":"PKP\/PVP combine chemotherapy in the treatment of multiple myeloma patients with vertebral pathological fractures: minimum 3-year follow-up of 108 cases","volume":"14","author":"Yao","year":"2019","unstructured":"Yao X, Xu Z and Du X. PKP\/PVP combine chemotherapy in the treatment of multiple myeloma patients with vertebral pathological fractures: minimum 3-year follow-up of 108 cases. J Orthop Surg Res 2019; 14: 42.","journal-title":"J Orthop Surg Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","unstructured":"Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG and Terpos E. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J 2019; 9: 27.","journal-title":"Blood Cancer J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s00277-023-05202-9","article-title":"Risk-benefit ratio of percutaneous kyphoplasty and percutaneous vertebroplasty in patients with newly diagnosed multiple myeloma with vertebral fracture: a single-center retrospective study","volume":"102","author":"Xiang","year":"2023","unstructured":"Xiang QQ, Chu B, Lu MQ, Shi L, Gao S, Wang YT, Fang LJ, Ding YH, Zhao X, Chen Y, Wang MZ, Hu WK, Wang LF, Sun K and Bao L. Risk-benefit ratio of percutaneous kyphoplasty and percutaneous vertebroplasty in patients with newly diagnosed multiple myeloma with vertebral fracture: a single-center retrospective study. Ann Hematol 2023; 102: 1513-1522.","journal-title":"Ann Hematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"9998927","DOI":"10.1155\/2023\/9998927","article-title":"Increased expression of SRSF1 predicts poor prognosis in multiple myeloma","volume":"2023","author":"Zhang","year":"2023","unstructured":"Zhang J, Wang Z, Wang K, Xin D, Wang L, Fan Y and Xu Y. Increased expression of SRSF1 predicts poor prognosis in multiple myeloma. J Oncol 2023; 2023: 9998927.","journal-title":"J Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/ijlh.14024","article-title":"Increased expression of CEP72 predicts poor prognosis in multiple myeloma","volume":"45","author":"Guo","year":"2023","unstructured":"Guo D, Lu J, Ji H, Lin Z, Hong L, Huang H and Liu H. Increased expression of CEP72 predicts poor prognosis in multiple myeloma. Int J Lab Hematol 2023; 45: 317-327.","journal-title":"Int J Lab Hematol"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Divekar O, Ajayi B, Barkham B, Bernard J, Bishop T, Reyal Y, Willis F, Boyd K, Lui D and Coomber R. Chemotherapy may obviate prophylactic femoral nail surgery for multiple myeloma patients with high mirels’ score lesions and impending pathological hip fracture. Cureus 2023; 15: e37670.","DOI":"10.7759\/cureus.37670"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1615\/JLongTermEffMedImplants.2022044050","article-title":"Treatment of pathological fracture of radius due to multiple myeloma with elastic intramedullary nail and cement augmentation: expanding the indications of elastic nails","volume":"33","author":"Ntontis","year":"2023","unstructured":"Ntontis Z, Koutserimpas C, Chaniotakis K, Stavrakakis I, Samonis G and Alpantaki K. Treatment of pathological fracture of radius due to multiple myeloma with elastic intramedullary nail and cement augmentation: expanding the indications of elastic nails. J Long Term Eff Med Implants 2023; 33: 67-70.","journal-title":"J Long Term Eff Med Implants"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrd.2015.39","article-title":"Age of antibody therapeutics dawns for multiple myeloma","volume":"15","author":"Kingwell","year":"2016","unstructured":"Kingwell K. Age of antibody therapeutics dawns for multiple myeloma. Nat Rev Drug Discov 2016; 15: 5-6.","journal-title":"Nat Rev Drug Discov"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D&#x2019","year":"2022","unstructured":"D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall’Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M and Sonneveld P. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European myeloma network (EMN) report within the HARMONY project. J Clin Oncol 2022; 40: 3406-3418.","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","unstructured":"Hagen P, Zhang J and Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J 2022; 12: 83.","journal-title":"Blood Cancer J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s10238-023-00992-8","article-title":"A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients","volume":"23","author":"Ren","year":"2023","unstructured":"Ren L, Xu J, Li J, Xu T, Yang Y, Wang W, Ren Y, Gu S, Chen C, Wei Z, Zhuang J, Wang Z, Ji L, Cheng L, Wang W, Cheng Z, Ke Y, Yuan L and Liu P. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. Clin Exp Med 2023; 23: 2583-2591.","journal-title":"Clin Exp Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.1038\/s41598-020-69616-5","article-title":"PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model","volume":"10","author":"Lee","year":"2020","unstructured":"Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ and Kim BS. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model. Sci Rep 2020; 10: 12641.","journal-title":"Sci Rep"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0155698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:56Z","timestamp":1766022836000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/6\/ajcr0155698.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/vfdm5811","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2024]]}}}